Guided Therapeutics' distribution partner for Indonesia placed a fully paid order for 2,000 high margin, single use Cervical Guides, to be used with the existing installed base of LuViva advanced cervical scans.
Image: Guided Therapeutics receives order for LuViva in Indonesia yodiyim/FreeDigitalPhotos.net
The purchase, which includes only high-margin Cervical Guides, further indicates that installed LuViva units are seeing increased usage in hospitals and clinics, and bolsters reports that medical practitioners in Indonesia are comfortable using the LuViva test as an alternative to conventional for cervical cancer screening.
This most recent orders marks the ninth time LuViva equipment has been ordered for Indonesia, with total sales revenue over $350,000; 60% of which has shipped within the past year.
Guided Therapeutics CEO said Gene Cartwright “We are very encouraged that usage of LuViva in Indonesia is increasing, as clinics and hospitals are seeing the benefit of screening with LuViva, which provides an immediate result so that treatment, if needed, can begin more quickly.
“The increase in sales of the high margin Cervical Guides per installed device is an important component to reaching profitability. It also is an indicator of the overall satisfaction doctors, their clinics and patients have with our product.”
There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide. The world market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9bn by 2020.
About LuViva Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing.
LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva Cervical Guide single-use patient interface and calibration disposable.
Source: Company Press Release